and Daily SiHy lenses and Bausch + Lomb ULTRA ® in our contact lens business. Surgical segment revenue was $231 million for the fourth quarter of 2024, as compared to $204 million for the fourth ...

Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake.

Bausch & Lomb is one of the largest vision care companies ... With an upcoming launch of multifocal and toric lenses in the Infuse line (daily silicone hydrogels), we expect Bausch to win over ...

"Underpinning our recent success is a commitment to long-term, profitable growth," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Our refocused pipeline is now filled with promise and ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 ...